Aura Biosciences (AURA) Income towards Parent Company (2020 - 2026)

Aura Biosciences (AURA) has 7 years of Income towards Parent Company data on file, last reported at -$33.7 million in Q1 2026.

• Quarterly Income towards Parent Company fell 22.57% year-over-year to -$33.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.2 million (up 92.52% YoY) and the FY2025 annual result came in at -$958000.0, up 98.91% from the prior year.
• Income towards Parent Company retreated to -$33.7 million in Q1 2026, from $79.7 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $79.7 million in Q4 2025 to a low of -$74.3 million in Q1 2022.
• A 5-year average of -$23.0 million and a median of -$22.1 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2022 — Income towards Parent Company tumbled 1135.3% — and 2025, when it jumped 396.12%.
• Tracing AURA's Income towards Parent Company over 5 years: stood at -$18.4 million in 2022, then slipped by 20.4% to -$22.1 million in 2023, then dropped by 21.58% to -$26.9 million in 2024, then surged by 396.12% to $79.7 million in 2025, then slumped by 142.28% to -$33.7 million in 2026.
• The last three Income towards Parent Company figures came in at -$33.7 million (Q1 2026), $79.7 million (Q4 2025), and -$26.1 million (Q3 2025), per Business Quant data.